Smart Robotic Knee/Ankle Prothesis for Amputations

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Exoskeleton and Prosthetic Intelligent Controls Lab, Atlanta, GA
Amputations
Robotic Knee/Ankle Prosthesis - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This work will focus on new algorithms for powered prostheses and testing these in human subject tests. Individuals with above knee amputation will walk with a robotic prosthesis and ambulate over terrain that simulates community ambulation. The study will compare the performance of the advanced algorithm with their take-home device, as well as with the robotic system that does not use an advanced algorithm.

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Self-selected Walking Speed

Trial Safety

Trial Design

1 Treatment Group

Smart Robotic Knee/Ankle Prothesis
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Smart Robotic Knee/Ankle Prothesis · No Placebo Group · N/A

Smart Robotic Knee/Ankle Prothesis
Device
Experimental Group · 1 Intervention: Robotic Knee/Ankle Prosthesis · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
Closest Location: Exoskeleton and Prosthetic Intelligent Controls Lab · Atlanta, GA
Photo of Atlanta  1Photo of Atlanta  2Photo of Atlanta  3
2020First Recorded Clinical Trial
1 TrialsResearching Amputations
2 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.